Celebrating the special bond between patients and their care team
A hemodialysis professional shares how his patient inspires him and touches his life every day.
The complementary effects of using Parsabiv® with vitamin D and phosphate binders1-7
Select a button below to see how different regimens could affect sHPT.
D & Phosphate
D & Phosphate
Vitamin D and Phosphate Binders
activation of calcium-
Ca & P released
release of more
Ca & P from the
Approximately 7 times more patients given Parsabiv® achieved > 30% reduction in mean PTH8
P < 0.001
Results are combined from two 26-week, randomized, double-blind, placebo-controlled studies comparing Parsabiv® with placebo in patients with chronic kidney disease (CKD) on hemodialysis with intact parathyroid hormone (iPTH) > 400 pg/mL and corrected calcium ≥ 8.3 mg/dL; N = 1023. Patients in both treatment arms could be treated with vitamin D sterols and/or phosphate binders. Mean baseline iPTH in the Parsabiv® group and placebo group were 847 pg/mL and 836 pg/mL, respectively. The primary endpoint of each study was the proportion of patients who achieved a > 30% reduction from baseline in mean iPTH during the EAP (defined as weeks 20 through 27, inclusive).1,9,10
*Vitamin D and/or phosphate binders, if prescribed.10
EAP = efficacy assessment phase.
Administration, storage, and handling video
Watch this video, geared specifically toward nurses, on how to store and administer Parsabiv®.
STORING & HANDLING
Learn about dose sizes
and safe storage
PREPPING PARSABIV®Vial handling best practices
and withdrawal tips
Parsabiv® educational tools that cover all aspects of the only IV calcimimetic